AVAC in the News
“Weakening fundamental scientific infrastructure now risks slowing progress well beyond HIV to other disease areas.”
Results
showing 1-10 of 824
NIH Budget Cuts Threaten HIV Research
For Think Global Health, AVAC's Director of Research Engagement Stacey Hannah and Executive Director Mitchell Warren co-authored a piece warning that the Trump administration's proposed funding cuts to the National Institutes of Health could derail the vaccine needed to end HIV. "Vaccine science is cumulative: today's breakthroughs depend on decades of investment," wrote Hannah and Mitchell.
Source: Think Global Health
Delivering the HIV Prevention Ambition: Partnership, Country and Community Leadership, and Shared Accountability
Mitchell Warren, Executive Director of AVAC and Co-Chair of the Global HIV Prevention Coalition, stressed that prevention must remain central to the overall HIV response saying, “HIV prevention is core to the HIV response. It is core to sustainability, core to helping ensure people living with HIV can access treatment."
Source: Global HIV Prevention Coalition
Is a game-changing HIV prevention drug meeting global demand?
Positively Aware reports on the expansion of lenacapavir across low-income countries as advocates push for funding, access and accountability. “The introduction of LEN is faster than we’ve ever seen a new product get to market,” says Mitchell Warren, the longtime executive director of AVAC. “But it’s still not fast enough to deliver the impact that’s needed.”
Source: Positively Aware
How Do We Protect Decades of Global Health Progress Amid Mounting Funding Cuts?
Devex spoke with top health leaders to find out how the sector must adapt to the changing funding environment. AVAC Executive Director Mitchell Warren, "what's key to that is debt relief for these countries. Many countries are spending more servicing their debt than they are in their health issues at home."
Source: Devex
Advocacy groups urge U.S. to share experimental Ebola drug for outbreak trials
AVAC joined fellow advocacy groups in calling on the US government to make an experimental Ebola treatment available for clinical trials and emergency use in countries responding to the Ebola outbreak.
Source: Reuters
Zambian AIDS Patients Pay the Price of Dispute Over America’s Demand for Preferential Access to Minerals
“Where USAID was created to support economic development in other countries, this new approach is about extracting value for the United States and diminishes safety, security and prosperity in the United States and in other countries,” the executive director of the anti-AIDS coalition AVAC, Mitchell Warren, tells the Sun.
Source: The Sun
When Budgets are Tight, How Do We Do More with Less? [VIDEO]
"We actually need to start prioritizing differently and better and making sure we're not doing things that aren't adding value and delivering impact," said AVAC Executive Director Mitchell Warren, speaking with Devex at WHA79.
Source: Devex
The Trump Administration’s Long-Awaited Global Health Nomination
“I am relieved that this Administration finally nominated an Ambassador for Global Health Security and Diplomacy,” Mitchell Warren, executive director of AVAC, tells me. The timing matters, he says, given pressing global health threats, such as the ongoing Ebola outbreak, and the US’ commitment to scale up lenacapavir for HIV prevention.
Source: Devex
Did US Aid Cuts Break Precisely the Things We Need Most for the Lenacapavir Rollout?
“South Africa is home to the largest and most successful PrEP programme in the world, even though it has not delivered the impact we wanted,” says Mitchell Warren, Executive Director of AVAC. Warren’s point about the impact not being what we wanted, refers to the fact that, comparatively large as our PrEP programme is, uptake has been much lower than what was hoped.
Source: Spotlight
Accountability, Resistance, and Dissent in Public Health
President Trump’s fiscal year 2026 budget proposed a 50% cut in the CDC’s funding, slashing nearly five billion dollars. Chronic disease prevention funding was cut, along with US$12 billion for public health programs to states. Funding for disease surveillance and vaccines for children and uninsured adults were similarly targeted. Resistance has also come from litigation, filed by organizations such as Public Citizen, the American Public Health Association, the AIDS Vaccine Advocacy Coalition, and the Global Health Council. Outcomes have been mixed.
Source: Health and Human Rights
showing 1-10 of 824